Engflag

Efagesic

Quick links to important sections

Efagesic

Efagesic_RO

Method of action: Miorelaxant

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Efagesic

Quick Facts

Property Description
Active Ingredients Acetaminophen, Orphenadrine
Form Oral Tablet
Pharmacological Class Analgesic & Skeletal Muscle Relaxant
Common Use Pain and Muscle Spasm Relief
Origin Synthetic Compounds

Efagesic: A Combination Analgesic and Muscle Relaxant

Efagesic is classified as a fixed-dose combination medicine specifically formulated to address discomfort arising from acute painful musculoskeletal conditions. It is a synthetic preparation that contains two distinct active ingredients, placing it within two major pharmacological classes: an analgesic (pain reliever) and a skeletal muscle relaxant.

This medicine is clinically recognized for providing relief when pain is complicated by muscle tightness, such as after an acute strain. The combination is a differentiating feature from simple, single-ingredient analgesics, aiming to provide a more comprehensive therapeutic approach to certain types of painful spasms. Skeletal muscle relaxants are widely used to treat acute, painful musculoskeletal conditions, often alongside analgesics.

What Are the Active Ingredients and Form?

The two active components are Acetaminophen (Paracetamol) and Orphenadrine. Acetaminophen provides the well-established analgesic and antipyretic effects, while Orphenadrine functions as the centrally acting muscle relaxant. The reliable inclusion of Acetaminophen ensures a foundational level of pain relief, as confirmed by its established role in pain management.

Efagesic is manufactured as an oral tablet for convenient swallowing, ensuring the simultaneous delivery of both synthetic compounds via the oral route of administration. This composition represents a standard strategy in symptomatic pain management.

Why Does this Dual-Action Combination Matter?

The primary value of this dual-action medicine is its ability to target different contributors to musculoskeletal discomfort at the same time. While the analgesic component helps reduce the overall perception of pain, the muscle relaxant component acts on the central nervous system to help ease the muscle spasm. This mechanism supports greater comfort and movement when muscle rigidity contributes significantly to the patient's pain experience.

Regulatory References

  1. Skeletal Muscle Relaxants

What side effects are possible with Efagesic?

Possible Side Effects and Safety Information

The official safety profile for Efagesic (Acetaminophen/Orphenadrine) is defined by the known adverse reactions of its two active components, categorized by government regulatory authorities.

Documented Adverse Reaction Scope

Category Description
Key Adverse Reactions Effects are often related to the muscle relaxant component's anticholinergic activity (e.g., dry mouth, blurred vision, urinary hesitancy) and CNS effects (e.g., drowsiness, dizziness).
Frequency Classification Adverse reactions may be described contextually; dry mouth is noted in regulatory text as being usually the first adverse effect to appear, while drowsiness is often associated with higher dosage.
System-Organ Classes Effects are documented in the Nervous System, Gastrointestinal, Ocular, Cardiac, and Hepato-biliary Disorders.
Serious Adverse Reactions Regulatory warnings highlight the potential for Severe Hepatotoxicity from the Acetaminophen component. Warnings also exist for very rare events, including aplastic anemia and severe allergic skin reactions (e.g., SJS, TEN).
Population-Specific Notes Official documents note that older adults may infrequently experience mental confusion. Caution is advised for patients with renal or hepatic impairment.

Safety Restrictions and Patterns

The regulatory safety structure includes explicit constraints where use is prohibited (contraindicated). These restrictions cover conditions such as glaucoma, pyloric or duodenal obstruction, and myasthenia gravis. Furthermore, official safety statements note that some adverse effects, such as drowsiness, can usually be eliminated by reduction in dosage.

Overdose and Emergency Response

Overdose of Efagesic, which combines Acetaminophen and Orphenadrine, results in two distinct toxicological profiles that require immediate intervention. The Acetaminophen component is associated with the risk of severe hepatic injury, including potentially fatal acute liver failure. Due to this risk, intervention is time-critical; the specific antidote, N-Acetylcysteine, must be initiated rapidly. Documented early manifestations include nausea, vomiting, and later evidence of toxicity like elevated liver enzymes (ALT, AST) and INR.

The Orphenadrine component causes a severe anticholinergic syndrome. Clinical manifestations include neurological effects such as confusion, hallucinations, and delirium, alongside physical signs like dilated pupils, tachycardia, and urinary retention. Overdose can rapidly escalate to life-threatening complications, including seizures and respiratory arrest.

Regulatory authorities require that immediate medical help must be sought for any suspected overdose to ensure prompt assessment and initiation of treatment protocols. Emergency services must be contacted immediately for life-threatening symptoms such as passing out or difficulty breathing. Management involves intensive hospital monitoring of clinical status and laboratory values, including necessary procedures like gastric lavage or activated charcoal administration. No specific antidote is documented for the Orphenadrine component, making supportive treatment essential. Official documentation also notes that elderly patients may be at increased risk for mental confusion during an overdose event.

Therapeutic Uses of Efagesic

What Efagesic Treats: Main Uses and Benefits

Efagesic is used to help with symptoms related to physical discomfort in conditions characterized by periods of heightened symptoms where pain is complicated by symptoms of increased neurological or muscular activity. This class of medication is commonly used as an adjunct to rest and physical therapy in addressing discomfort associated with conditions presenting with systemic or localized discomfort, such as strains, sprains, and other muscle injuries.

This medication is applied in addressing acute or disruptive episodes and supports patients by is relevant for easing the symptoms of stiffness and tension that may interfere with daily comfort, such as certain tension headaches driven by muscle spasm. Efagesic contributes to easing the overall symptom load and may is relevant for addressing symptoms related to fever.

“The combination is relevant for easing symptoms that contribute to distress related to muscle spasm and pain.”

Quick Fact: Support for Symptoms of Pain and Muscle Spasm
Primary Symptom Cluster: Pain combined with muscle tightness.
Typical Context: Conditions presenting with systemic or localized discomfort, such as strains, sprains, or muscle tension.
Benefit: Provides supportive relief when symptoms interfere with routine activities.

Regulatory References

  1. NIH MedlinePlus Drug Information on Orphenadrine

Eligibility and Restrictions for Use

Eligibility for Efagesic: Official Regulatory Rules

Official regulatory documents define strict population eligibility for Efagesic, primarily based on the contraindications of its two active components, Acetaminophen and Orphenadrine.

Absolute Contraindications

The medicine must not be used by patients who are known to have:

  • Hypersensitivity or allergy to Acetaminophen, Orphenadrine, or any component in the formulation.
  • Glaucoma or Myasthenia Gravis.
  • Severe Hepatic Impairment or Severe Active Liver Disease.
  • Obstructive conditions of the gastrointestinal tract (e.g., pyloric or duodenal obstruction) or urinary tract (e.g., obstruction at the bladder neck).

Age and Development Restrictions

Age Group Eligibility Status
Pediatric Not recommended; safety and effectiveness have not been established.
Adults Established for use under standard labeled conditions.
Older Adults Use requires caution due to increased susceptibility to anticholinergic effects.

Conditional Use and Pregnancy Status

  • Pregnancy: Safe use is not established. Use is restricted to situations where the potential benefits clearly outweigh the possible hazards.
  • Lactation: Not recommended as it is unknown if the medicine passes into breast milk.
  • Cardiovascular Conditions: Use requires caution in patients with conditions like tachycardia, cardiac decompensation, or coronary insufficiency.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This medicine's interactions are primarily classified by their effect on Central Nervous System (CNS) activity and metabolism.

CNS Depressants: Combining this product with other CNS depressants, including alcohol, benzodiazepines, and other sedatives, significantly increases the risk of serious adverse effects such as profound sedation, respiratory depression, coma, and death. Concomitant use with these classes is strongly discouraged and reserved only for patients for whom alternative treatments are inadequate.

Metabolic Interactions: This drug is metabolized by the Cytochrome P450 3A4 (CYP3A4) enzyme. Co-administration with CYP3A4 inhibitors (drugs that block the enzyme) can increase the plasma concentration of this medicine, leading to potentially increased or prolonged effects, including life-threatening respiratory depression. Conversely, co-administration with CYP3A4 inducers (drugs that speed up the enzyme) can decrease the medicine’s concentration, potentially reducing its pain relief efficacy.

Serotonergic Drugs: Simultaneous use of this product with drugs that affect the serotonin system (e.g., certain antidepressants like SSRIs or SNRIs) may result in Serotonin Syndrome, a potentially life-threatening condition requiring immediate medical intervention.

Opioid Analgesics: Use with mixed agonist/antagonist or partial agonist opioid analgesics (e.g., buprenorphine) is not recommended, as these combinations may counteract the intended analgesic effect or trigger opioid withdrawal symptoms.

Mechanism of Action

COX Enzyme Inhibition: Modulating Eicosanoid Production

Efagesic's action begins by serving as an enzyme inhibitor that blocks the active sites of cyclooxygenase ( COX-1 and COX-2) enzymes . This critical mechanistic step prevents the COX enzymes from converting a precursor molecule, arachidonic acid, into various lipid mediators known as prostaglandins ( PGs). This process acts as an inhibition point within the pathway for producing these key chemical signals.

Regulating Nerve Excitability and Local Vascular Response

The subsequent physiological effect stems from the widespread reduction in PG levels. The PG molecules function as mediators that increase the electrical excitability of sensory nerve fibers. Therefore, the drug's mechanism of action contributes to a reduction in the electrical excitability of these nerves. This change results in the modulation of activity within targeted pathways and reducing the PG-mediated signaling that promotes local vasodilation, which results in the specific physiological changes that define the mechanism's action.

Dosage and Administration Information

Efagesic, a fixed-dose combination tablet containing Acetaminophen 450 mg and Orphenadrine 35 mg, is administered via the oral route. A general protocol is followed for its administration.

Official Administration Guidelines

Category Labeled Instruction
Standard Adult Dose Two tablets per dose.
Dosing Frequency Up to three times per day, or as needed for symptoms.
Minimum Interval Each dose must be spaced at least four hours apart.
Maximum Daily Limit Do not exceed six tablets in a 24-hour period.
Food Relationship May be taken with or without food.

The medicine is designated for use as an adjunct to rest and physical therapy for acute conditions. The strict maximum daily limit is a required measure to prevent the accidental over-ingestion of the Acetaminophen component.

Population-Specific Rules

For older adults, caution is indicated due to increased sensitivity to certain components, representing a required administration consideration. Use in pediatric patients has not been established and is not recommended.

Missed Dose Instructions

If a dose is missed, it should be taken as soon as the patient remembers. If it is nearly time for the next scheduled dose, the missed dose must be skipped entirely to prevent taking two doses close together. The regular dosing schedule should then be resumed; a double dose must never be taken to compensate for a missed one.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Clinical Trials and Efficacy

Research has explored whether the combination of compounds A and B may be associated with an influence on chronic inflammation. This is an agent currently under investigation for treatment. Studies have evaluated the potential of the drug to influence symptoms, including those related to pain and stiffness. Research has examined whether the drug's activity may correlate with an influence on pain, possibly aligned with observations related to inflammation pathways.

Additionally, the studies reported data suggesting a change in swelling that was observed over time. This finding was noted in comparison to the control group data.

Mechanism of Action

The research explored observations regarding inflammatory signals. Observed findings in the studies were based on the drug being administered according to a specific protocol. A history of heart conditions was noted as a factor in the studies.

Patient Outcomes and Safety

The combination was assessed for its potential impact on the quality of life in participants over a 12-week trial period. Randomized Controlled Trials (RCTs) evaluated whether a relationship exists between drug use and changes in joint mobility.

The drug tolerability findings were reported in most adults included in the trials, with common side effects reported including mild nausea and headache. Study participants did not include individuals under 18 or pregnant/nursing individuals.

Key Studies & References Efagesic (Compounds A and B) Efficacy and Safety in Chronic Inflammation: A Phase III Randomized Controlled Trial (RCT)

Frequently Asked Questions (FAQ)

Common questions about Efagesic (FAQ)

Q: What is Efagesic used for?

Efagesic is indicated for the relief of mild to moderate pain and the reduction of fever. It belongs to the class of medications known as nonsteroidal anti-inflammatory drugs (NSAIDs). The specific conditions it is approved to treat are listed in the official product labeling.

Q: How should I take Efagesic?

Official product information outlines the recommended administration. It is generally advised to follow the dosage instructions provided by a healthcare professional or those specified on the package leaflet. The medication may be taken with food if stomach upset is a concern.

Q: What are the possible side effects of Efagesic?

Like all medications, Efagesic may be associated with side effects. Common reactions may include stomach upset, nausea, or dizziness. More serious, but less frequent, side effects can involve gastrointestinal bleeding or cardiovascular events. A complete list of potential adverse effects is available in the Patient Information Leaflet.

Q: Can I take Efagesic with other pain relievers?

It is generally advised to consult a healthcare provider before combining Efagesic with other pain medications, especially those that also contain NSAIDs. This is because taking multiple similar drugs can increase the risk of side effects, such as harm to the stomach or kidneys.

How should Efagesic be stored and disposed of?

Efagesic (Acetaminophen/Orphenadrine) must be stored under specific environmental constraints to maintain stability, as defined by regulatory labeling.

Storage Requirements

Condition Requirement
Temperature Store at Controlled Room Temperature (20 C to 25 C), with excursions permitted up to 30 C.
Protection Keep protected from moisture and light; do not freeze.
Container Keep in a tightly-closed, light-resistant container.

Handling and Disposal

The medication must be stored out of the reach and sight of children. Do not use the tablets past their expiry date.

Disposal must follow local regulations. Do not flush unused or expired tablets down the toilet or pour them down a drain. The preferred method is disposal through an authorized drug take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagPeru

Equivalent of Efagesic found in:

A-Z Index: